Section 4 of 6
Clinical evidence
271 evidence topics · 53 sources
Study summaries
BOND-003 cohort C
Objective
Registry objective: complete response at any time in BCG-unresponsive CIS
Publication objective: response, safety, and tolerability
Trial-in-progress objective: confirmation of monotherapy activity
Location and study date
Centres and regions
“BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sites were selected through a study team-led qualification process that evaluated feasibility, protocol alignment, operational capabilities, and regulatory readiness, as applicable.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Countries named in the trial-in-progress report
Proportion of participants enrolled in the United States
Enrollment status of Cohort C
Latest efficacy data cutoff and median follow-up
Next data release for Cohort C
Study design
Single-arm, open-label phase 3 design with separately analyzed cohorts
Global trial in BCG-unresponsive CIS-containing and papillary disease
Response assessment schedule and central confirmation
Mandatory bladder mapping at 12 months
Design stated by the company to follow the 2018 FDA guidance
Eligibility criteria
Key inclusion criteria in the publication
“We enrolled patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0-2 and pathologically confirmed, high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without resected high-grade Ta or T1 disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition of BCG-unresponsive disease
Registry inclusion criteria for Cohort C
Registry key exclusion criteria
Treatment
Dose and schedule in the publication
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose and schedule in the company annual report
Treatment courses
| Course | Schedule |
|---|---|
| Induction | “Weekly x 6” |
| Maintenance, year 1 | “Weekly x 3 Q3M for Year 1” |
| Maintenance, years 2 to 3 | “Weekly x 3 Q6M for Year 2-3” |
| Second induction | “Weekly x 6 for non-responders” |
Registry arm description: DDM pretreatment and dosing weeks
Instillation process used in Cohort C and in later studies
Study outcomes
Rationale for using complete response at any time as the primary endpoint
Primary endpoint and secondary endpoints in the trial-in-progress report
Primary endpoint in the company annual report
Registry secondary outcomes for Cohort C
“Cohort C: Duration of response (DOR)” (opens the source at this quote in a new tab)
“Cohort C:Complete Response rate at 12 months” (opens the source at this quote in a new tab)
“Cohort C and Cohort P : Cystectomy free survival” (opens the source at this quote in a new tab)
“Cohort C: Assess overall survival” (opens the source at this quote in a new tab)
Definition of complete response used in the trial
Cystectomy-free survival: definition and rationale
FDA 2018 guidance: complete response rate as the primary endpoint of a single-arm trial
FDA 2018 guidance: confidence interval, duration of response, and assessment at 3 months
FDA 2024 draft guidance: complete response as an interpretable single-arm endpoint
International Bladder Cancer Group 2016: single-arm designs and clinically meaningful response rates
“Single-arm designs may be relevant for the BCG-unresponsive population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the high risk of disease progression, a placebo-controlled arm is not ethical.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with BCG-unresponsive CIS, we recommend an initial CR rate of 50% at 6 months and durable response rates of 30% at 12 months and 25% at 18 months as clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recent FDA–AUA public workshop, some panel members felt that an initial CR rate of 40% to 50% at 6 months and a durable response rate of at least 30% for 18 to 24 months, with the lower bound of the 95% CI excluding 20%, could be clinically meaningful in the BCG-refractory CIS population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SITC and International Bladder Cancer Group 2023: complete response rate and duration in single-arm trials
“For populations with CIS, CR rate and duration are clinically meaningful end points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random assignment in this setting may be less acceptable to patients/providers, and single-arm trial designs have been permitted by the US Food and Drug Administration (FDA)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per FDA guidance, CR rate and duration should be benchmarked against historical agents or modern options (eg, valrubicin, pembrolizumab, gemcitabine and docetaxel, or nadofaragene firadenovec).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the registry
Participants enrolled, treated, and analyzed for efficacy
“115 patients were enrolled in the study and 112 received cretostimogene” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Efficacy and safety analysis populations
“The primary endpoint was centrally confirmed complete response at any time in patients who received at least one dose of cretostimogene and completed the 3-month assessment; safety was assessed in those who received at least one dose of cretostimogene.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Central confirmation, landmark and Kaplan-Meier analyses
Population labeled intention to treat for the 24-month landmark
Subgroup definitions for prior-therapy analyses
Results
Participant disposition
Treatment completion, discontinuation, and missed doses
Baseline characteristics
Demographics and disease characteristics, safety population
| Characteristic | n or value | % |
|---|---|---|
| Male | “83” | “74.1” |
| Female | “29” | “25.9” |
| Age, mean (SD), years | “72.9 (9.19)” | |
| Age, median (range), years | “74.0 (43-90)” | |
| Age under 65 years | “19” | “17.0” |
| Age 65 to under 75 years | “43” | “38.4” |
| Age 75 years or older | “50” | “44.6” |
| Prior BCG instillations, median (range) | “12 (7 – 66)” | |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least 1 prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |
Race, age group, and prior therapy summary
Second-line and prior intervening chemotherapy subgroups
Efficacy results
Primary endpoint: complete response at any time, June 23, 2025 cutoff
Complete response at 12 and 24 months, June 23, 2025 cutoff
| Landmark | CR rate (95% CI) | Participants in CR | CR by Kaplan-Meier estimate (95% CI) |
|---|---|---|---|
| 12 months | “46.4% (36.9, 56.1)” | “51 out of 110 patients” | “50.7% (40.9, 59.8)” |
| 24 months | “41.8% (32.5, 51.6)” | “46 out of 110” | “42.4% (32.7, 51.7)” |
Complete response at 12 months: confidence interval reported in later presentations
Duration of response, June 23, 2025 cutoff
Duration of response rates attributed to the June 23, 2025 cutoff in September 2025
Progression to muscle-invasive disease
Radical cystectomy: timing and pathologic stage
| Measure | Value |
|---|---|
| Cystectomy any time after first recurrence, n (%) | “18 (16.4%)” |
| Cystectomy within the first year of recurrence, n (%) | “17 (15.5%)” |
| Weeks from recurrence or progression to cystectomy, median (Q1, Q3) | “20.0 (14.4, 26.7)” |
| Stage T0, n (%) | “1 (0.9)” |
| Stage CIS, n (%) | “9 (8.2)” |
| Stage HG Ta, n (%) | “1 (0.9)” |
| Stage T1, n (%) | “4 (3.6)” |
| Stage T2A, n (%) | “1 (0.9)” |
| Stage T2B, n (%) | “1 (0.9)” |
| Stage N2, n (%) | “1 (0.9)” |
| Participants with T0 or NMIBC at cystectomy | “15/18 (83.3%) were T0 or NMIBC” |
Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation
Complete response in second-line and prior intervening chemotherapy subgroups
Exploratory urinary tumor DNA analysis
Complete response and duration of response at the September 30, 2024 cutoff
Complete response at 24 months and duration of response at the March 14, 2025 cutoff
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events in the publication
“71 (63%) of 112 patients had at least one treatment-related adverse event, the most common being bladder spasm in 28 (25%) patients, pollakiuria in 25 (22%) patients, and micturition urgency in 23 (21%) patients; there were no grade 3 or 4 treatment-related adverse events and no treatment-related discontinuations or deaths.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two (2%) patients had serious treatment-related adverse events (one non-infective cystitis and one urinary bladder haemorrhage, both grade 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff
| Preferred term (MedDRA v.26.1) | Any grade, n (%) | Grade 3 or higher, n (%) |
|---|---|---|
| At least 1 treatment-related adverse event | “71 (63.4%)” | “0 (0)” |
| Bladder spasm | “28 (25.0%)” | “0 (0)” |
| Pollakiuria | “25 (22.3%)” | “0 (0)” |
| Urgency | “23 (20.5%)” | “0 (0)” |
| Dysuria | “21 (18.8%)” | “0 (0)” |
| Hematuria | “15 (13.4%)” | “0 (0)” |
Severity, resolution, and serious treatment-related adverse events
Study limitations
Summary: limitations of the BOND-003 Cohort C evidence
- Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
- Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
- Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
- Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
- Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
- Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
- Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.
FDA 2024 draft guidance: limits of single-arm trials
FDA 2018 guidance: cystectomy delay as an endpoint
Progression as an endpoint in BCG-unresponsive trials
Company risk statements on topline data and regulatory sufficiency
BOND-003 cohort P
Objective
Registry objective for Cohort P
Company description of the cohort's purpose
Population evaluated as presented at congress
Location and study date
Countries enrolling in Cohort P per registry
Registry dates for the whole BOND-003 study
| Field | Registry entry |
|---|---|
| Study start | “Study Start (Actual) 2020-10-27” |
| Primary completion | “Primary Completion (Estimated) 2030-06-16” |
| Study completion | “Study Completion (Estimated) 2031-12-24” |
Enrollment status reported in a 2025 trial-in-progress poster
Geographic distribution of enrolled participants
Study design
Single-arm, open-label design with intravesical administration
Registry design details
Response assessment schedule as stated in November 2026
Regulatory role of the cohort after FDA feedback, November 2026
Phase designation in the November 2026 investor presentation
Phase designation in company filings and releases
Eligibility criteria
Cohort P inclusion criteria
Key exclusion criteria shared by Cohorts C and P
Definition of BCG-unresponsive papillary disease as presented at congress
Treatment
Dose, transduction-enhancing agent, and schedule per registry
Induction, maintenance, and second induction courses
Study outcomes
Rationale for using high-grade event-free survival as the primary endpoint
Primary endpoint per registry and congress presentations
Primary endpoint per the Form 10-K description of the cohort
Definition of high-grade event-free survival used in the analysis
FDA recommendation for resected papillary disease
International Bladder Cancer Group recommendations for papillary disease
“Primary end points should include time to recurrence or recurrence-free survival (RFS) for fully resected papillary disease (because these patients have no evidence of disease at study entry)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with papillary disease that is BCG unresponsive, we consider recurrence-free rates of 30% at 12 months and 25% at 18 months as clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In scenarios where patients with CIS (with or without papillary disease) and papillary-only disease are evaluated separately, CR rate at 6 months and RFS, respectively, are appropriate primary end points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RFS in this setting includes death as an event and not a competing risk, distinct from low- and intermediate-risk NMIBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Benchmarks cited by the sponsor for BCG-unresponsive papillary disease
Secondary endpoints per registry
Secondary and additional endpoints per congress presentations
Statistical analysis description
Number of participants (Planned and analyzed)
Participants treated and evaluable at the September 2025 data cutoff
Efficacy population stated in the November 2026 investor presentation
| Field | Cretostimogene, BOND-003 Cohort P |
|---|---|
| Efficacy population | “N=54” |
Participants in the initial analysis, April 2025
Description of analysis sets
Kaplan-Meier estimation and censoring
Separate analysis of the two cohorts
Results
Participant disposition
Follow-up, re-induction, cystectomy, and treatment completion
“Median follow-up: 6.0 months” (opens the source at this quote in a new tab)
“8 patients were re-induced at 3 months” (opens the source at this quote in a new tab)
“No patients underwent RC” (opens the source at this quote in a new tab)
“No treatment related discontinuations” (opens the source at this quote in a new tab)
“98.2% received all protocol defined treatments” (opens the source at this quote in a new tab)
Baseline characteristics
Demographics and disease characteristics of the safety dataset
| Characteristic | n | % |
|---|---|---|
| Male | “44” | “78.6” |
| Female | “12” | “21.4” |
| Age, mean (SD), years | “71.6 (9.3)” | |
| Age, median (range), years | “74.0 (45-87)” | |
| Age < 65 years | “13” | “23.2” |
| Age ≥ 65 and < 75 years | “18” | “32.1” |
| Age ≥ 75 years | “25” | “44.6” |
| ECOG PS 0 | “48” | “85.7” |
| ECOG PS 1 | “8” | “14.3” |
| HG Ta at study entry | “33” | “58.9” |
| HG T1 at study entry | “23” | “41.1” |
| Prior BCG instillations, median (range) | “9.0 (5 – 21)” |
Efficacy results
High-grade event-free survival at the September 2025 data cutoff
Same estimates labeled as high-grade recurrence-free survival on the SUO 2025 slide
High-grade event-free survival by tumor stage
| Time point | HG Ta | HG T1 |
|---|---|---|
| 3 months | “92.8% (3 mo)” | “100% (3 mo)” |
| 6 months | “75.9% (6 mo)” | “100% (6 mo)” |
| 9 months | “75.9% (9 mo)” | “87.5% (9 mo)” |
Progression, cystectomy, and metastatic disease
Company report of the topline results
Twelve-month and 24-month estimates as of November 2026
| Time point | Cretostimogene, BOND-003 Cohort P |
|---|---|
| 3 months | “95.7 [95% CI: 83.8, 98.9]” |
| 6 months | “84.6 [95% CI: 68.6, 92.9]” |
| 9 months | “80.4 [95% CI: 62.3, 90.4]” |
| 12 months | “Not Yet Reached” |
Initial results in the first 24 treated participants, April 2025, superseded in December 2025
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events reported in more than 10% of participants
| Preferred term | Any grade, n (%) | Grade ≥ 3, n (%) |
|---|---|---|
| Participants with ≥1 TRAE | “40 (71.4%)” | “0 (0)” |
| Bladder spasm | “26 (46.4%)” | “0 (0)” |
| Dysuria | “22 (39.3%)” | “0 (0)” |
| Pollakiuria | “14 (25.0%)” | “0 (0)” |
| Urgency | “11 (19.6%)” | “0 (0)” |
Severity, serious events, deaths, and dosing interruptions
“Safety data cutoff as of 01SEP2025” (opens the source at this quote in a new tab)
“Most AEs were Grade 1-2” (opens the source at this quote in a new tab)
“0% Grade ≥ 3 TRAEs, Serious TRAE, deaths” (opens the source at this quote in a new tab)
“No dose delays, missed doses due to TRAEs” (opens the source at this quote in a new tab)
“No treatment related discontinuations” (opens the source at this quote in a new tab)
Safety summary in the Form 10-K
Study limitations
Summary: limitations of the Cohort P evidence
- Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
- Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
- Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
- Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
- Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
- Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
- Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
- Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
- Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.
Single-arm design and interpretability of time-to-event endpoints
Cross-trial comparisons in sponsor materials
CORE-001
Objective
Study purpose in the ClinicalTrials.gov record
Study question in the published final results
Primary and secondary objectives in the clinical study protocol
Expected benefit of the combination in the clinical study protocol
Location and study date
Study dates, enrollment, and sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2020-12-08” |
| Primary completion (actual) | “2023-03-07” |
| Study completion (actual) | “2024-05-28” |
| Enrollment (actual) | “35” |
| Sites | “This study has 19 locations” |
Enrollment by country in the published final results
| Country | Participants, n (%) |
|---|---|
| USA | “30 (85.7)” |
| Korea | “5 (14.3)” |
Planned accrual period and end of long-term follow-up in the clinical study protocol
Data cutoffs for the final results
Publication and congress presentation of the final results
Study design
Single-arm, open-label design in the ClinicalTrials.gov record
| Design characteristic | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Collaborator | “Merck Sharp & Dohme LLC” |
Design overview and safety lead-in cohort in the clinical study protocol
Disease assessments and central review in the clinical study protocol
Trial design and Merck supply agreement in the annual report
Eligibility criteria
Key inclusion criteria in the clinical study protocol
Key exclusion criteria in the clinical study protocol
Definition of BCG-unresponsive disease and the 15-month assessment window in the ClinicalTrials.gov record
FDA guidance as the basis of the BCG-unresponsive definition in the clinical study protocol
Treatment
Treatment schedule in the published final results
Cretostimogene dose and schedule in the clinical study protocol
Bladder wash and instillation procedure with DDM in the clinical study protocol
Pembrolizumab dose and transition from every-3-week dosing in the clinical study protocol
Treatment arm in the ClinicalTrials.gov record
Dose concentration and dosing schedule in the annual report
Study outcomes
Rationale for using complete response at 12 months as the primary endpoint
Primary and secondary endpoints in the published final results
Mandatory bladder mapping at 12 months in the clinical study protocol
Definition of complete response in the clinical study protocol
Historical 12-month complete response rates cited as the basis for the null hypothesis in the clinical study protocol
Complete response rate with duration of response as the single-arm endpoint in FDA guidance
Clinically meaningful durable response rate at 12 months in International Bladder Cancer Group recommendations
Secondary endpoints in the clinical study protocol
“Complete response rate at any time” (opens the source at this quote in a new tab)
“Duration of response” (opens the source at this quote in a new tab)
“Cystectomy free survival” (opens the source at this quote in a new tab)
“Progression free survival” (opens the source at this quote in a new tab)
“Overall survival” (opens the source at this quote in a new tab)
Exploratory endpoints including viral shedding in the clinical study protocol
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the clinical study protocol
Target and actual enrollment in the ClinicalTrials.gov record
Participants treated and analyzed in the published final results
Description of analysis sets
Analysis populations in the clinical study protocol
Handling of participants without a 12-month assessment and time-to-event methods in the clinical study protocol
Safety analysis methods in the clinical study protocol
Evaluable-patient denominators in the annual report
Results
Participant disposition
Reasons for discontinuation without disease recurrence
Reasons for screen failure
Baseline characteristics
Baseline characteristics in the published final results
| Characteristic | n = 35 |
|---|---|
| Age, median | “72” |
| Age, range | “57–90” |
| Sex, male | “33 (94.3)” |
| Sex, female | “2 (5.7)” |
| ECOG 0 | “25 (71.4)” |
| ECOG 1 | “9 (25.7)” |
| ECOG 2 | “1 (2.9)” |
| Race, White | “27 (77.1)” |
| Race, Black/African American | “2 (5.7)” |
| Race, Asian | “5 (14.3)” |
| Race, unknown | “1 (2.9)” |
| Stage, CIS | “27 (77.1)” |
| Stage, CIS + high-grade Ta | “4 (11.4)” |
| Stage, CIS + high-grade T1 | “4 (11.4)” |
| Prior BCG courses, 2 | “18 (51.4)” |
| Prior BCG courses, 3 | “8 (22.9)” |
| Prior BCG courses, 4 | “2 (5.7)” |
| Prior BCG courses, 5 | “4 (11.4)” |
| Prior BCG courses, ≥6 | “3 (8.6)” |
Prior BCG instillations and persistent or recurrent disease in the interim presentation
| Characteristic | Quoted value |
|---|---|
| Number of prior BCG instillations, median (range) | “12 (9 - 30)” |
| Persistent high-risk NMIBC, n | “21” |
| Persistent high-risk NMIBC, % | “60” |
| Recurrent high-risk NMIBC, n | “14” |
| Recurrent high-risk NMIBC, % | “40” |
Participants enrolled at U.S. sites in a pooled demographic analysis
Efficacy results
Complete response at 12 months, 3 months, and 24 months in the published final results
Final results at the May 17, 2024 data cutoff: response durability, Kaplan-Meier estimates, progression-free and cystectomy-free survival
Complete response at any time, 12 months, and 24 months in the annual report
Correction to the key of the duration-of-response figure
Exploratory urinary minimal residual disease analysis across BOND-003 and CORE-001
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events in the published final results
Treatment-related adverse effects by maximum severity
| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | Total (N = 35), n (%) |
|---|---|---|---|---|
| Participants with at least one study drug-related treatment-emergent adverse effect | “9 (25.7)” | “18 (51.4)” | “5 (14.3)” | “32 (91.4)” |
| Bladder spasm | “13 (37.1)” | “4 (11.4)” | “0” | “17 (48.6)” |
| Fatigue | “11 (31.4)” | “2 (5.7)” | “0” | “13 (37.1)” |
| Dysuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Pollakiuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Hematuria | “5 (14.3)” | “1 (2.9)” | “0” | “6 (17.1)” |
| Micturition urgency | “4 (11.4)” | “2 (5.7)” | “0” | “6 (17.1)” |
| Diarrhea | “4 (11.4)” | “0” | “1 (2.9)” | “5 (14.3)” |
| Nocturia | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Hypothyroidism | “1 (2.9)” | “3 (8.6)” | “0” | “4 (11.4)” |
| Urinary tract infection | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Blood alkaline phosphatase increased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Ejection fraction decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Neutrophil count decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Adrenal insufficiency | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Immune-mediated hepatitis | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
Attribution of grade 3 or higher events and table inclusion rules
Author correction removing attribution of immune-related adverse effects from the abstract
“…all related to pembrolizumab” (opens the source at this quote in a new tab)
“has been removed from the Abstract.” (opens the source at this quote in a new tab)
“assessed by the treating physicians” (opens the source at this quote in a new tab)
“Related adverse effect to pembrolizumab…” (opens the source at this quote in a new tab)
Safety summary in the annual report
Grade 3 events and absence of grade 4 or 5 events in the interim presentation
“Grade 3 AE included (4 total patients)” (opens the source at this quote in a new tab)
“Autoimmune hepatitis” (opens the source at this quote in a new tab)
“Reduced ejection fraction” (opens the source at this quote in a new tab)
“Neutrophil count decreased” (opens the source at this quote in a new tab)
“Alkaline phosphatase increased” (opens the source at this quote in a new tab)
“Adrenal insufficiency” (opens the source at this quote in a new tab)
“Grade 4 / 5 AE – none observed” (opens the source at this quote in a new tab)
Adverse event grading and serious adverse event capture in the clinical study protocol
Study limitations
Summary
CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.
Discontinuation of long-term efficacy and survival follow-up under protocol amendment 7
Additional patient data may differ from data at the cutoff
Single-arm trials appropriate only while no effective therapy is available in FDA guidance
BOND-002
Objective
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-06-02” |
| Primary completion (actual) | “2018-08” |
| Study completion (actual) | “2019-02” |
| Number of sites | “This study has 17 locations” |
| Principal investigator | “Gary Steinberg, MD” |
Study design
Registered design: open-label, single-arm, phase 2
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Company description of the design and population
Eligibility criteria
Inclusion: high-grade NMIBC after prior intravesical therapy including BCG
Inclusion: carcinoma in situ, or recurrent Ta or T1 disease
Inclusion: cystectomy declined, age, and performance status
Prior therapy of the interim population
“All patients received at least 2 prior courses of intravesical therapy for CIS, with at least 1 being a course of BCG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had either failed BCG induction therapy within 6 months or had been successfully treated with BCG with subsequent recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Registered regimen
Company description of dose, induction, and maintenance
Study outcomes
Rationale for using durable complete response at 18 months as the primary endpoint
Registered primary endpoint: durable complete response proportion
Endpoint reported in the interim analysis: complete response at 6 months
Regulatory context for durable complete response in single-arm trials
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “66” |
Description of analysis sets
Interim efficacy set: participants with 6-month follow-up
Safety set: protocol participants and three additional treated patients
Results
Participant disposition
No evidence found.
Baseline characteristics
Tumor stage at entry in the interim population
Efficacy results
Complete response at 6 months: interim analysis
“Overall 6-month CR (95% CI) was 47% (32%-62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Considering 6-month CR for pathologic subsets, pure CIS was 58% (37%-78%), CIS ± Ta/T1 50% (33%-67%), and pure Ta/T1 33% (8%-70%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 months, the single patient that progressed to muscle-invasive disease had Ta and T1 tumors at baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No patients with pure T1 had 6-month CR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response at any time and duration of response: company report
Complete response at 6 and 12 months in CIS-containing disease: company report
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events at 6 months: interim analysis
“Treatment-related adverse events (AEs) at 6 months were most commonly urinary bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Immunologic treatment-related AEs included flu-like symptoms (12%) and fatigue (6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade III treatment-related AEs included dysuria (3%) and hypotension (1.5%). There were no Grade IV/V treatment-related AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related and serious adverse events: company report
Study limitations
Summary: limitations of BOND-002
- Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
- Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
- Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
- Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
- Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
- No results posted on ClinicalTrials.gov were identified.
BOND
Objective
Registered study purpose
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start | “2014-03” |
| Primary completion (actual) | “2016-06” |
| Number of sites | “This study has 7 locations” |
| Study chair | “Alex W Yeung, MBBS” |
Study design
Registered design: integrated phase 2/3 randomized controlled trial
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Inclusion: high-grade disease with carcinoma in situ after BCG
Inclusion: cystectomy indicated, age, and performance status
Exclusion criteria
Treatment
Experimental arm: CG0070 after DDM pretreatment
Control arm: investigator choice of intravesical chemotherapy or interferon
Study outcomes
Rationale for using complete response as the primary endpoint
Registered primary endpoint, phase 2 part: complete response at 9 months
Registered primary endpoint, phase 3 part: durable complete response at 15 months
Regulatory context for durable complete response in single-arm trials
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “22” |
Planned between-arm comparisons
Description of analysis sets
No evidence found.
Results
Participant disposition
Study termination
| Field | Quoted record |
|---|---|
| Reason for stopping | “Change in study design” |
| Study completion (actual) | “2016-06” |
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations of BOND
- BOND was registered as an integrated phase 2/3, open-label, randomized study of CG0070 against investigator choice of mitomycin C, interferon, valrubicin, or gemcitabine in participants with CIS-containing disease after BCG.
- The registry lists the study as terminated for a “Change in study design” with 22 participants enrolled, from March 2014 to June 2016.
- No results posted on ClinicalTrials.gov and no publication or company report of its efficacy or safety results were identified, so the study contributes no efficacy or safety data to this report.
- Eligibility allowed participants who had been “successfully treated with BCG, but subsequently found to have recurrence”, so the registered population differs from the BCG-unresponsive population of BOND-003.
V-0046
Objective
Purpose stated in the phase 1 publication
Location and study date
Registered study dates, sponsor, and sites
| Field | Quoted record |
|---|---|
| Study start | “2005-04” |
| Primary completion (estimated) | “2008-10” |
| Study completion (estimated) | “2010-09” |
| Number of sites | “This study has 10 locations” |
Study design
Registered design: phase 1 dose escalation
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Treatment
Dose levels and schedules administered
“A total of 35 patients received single or multiple (every 28 days × 3 or weekly × 6) intravesical infusions of CG0070 at 1 of 4 dose levels (1 × 10(12), 3 × 10(12), 1 × 10(13) or 3 × 10(13) viral particles).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Registered primary endpoint: maximum tolerated or maximum feasible dose
Primary goals stated at study start: safety and maximum tolerated dose
Response and pharmacokinetic assessments
“Response to treatment was based on cystoscopic assessment and biopsy or urine cytology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Urine and plasma CG0070, and granulocyte-monocyte colony-stimulating factor were measured in all patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “75” |
Description of analysis sets
Results
Participant disposition
Participants treated by schedule and dose range
Baseline characteristics
Tumor stage of enrolled participants
Efficacy results
Complete response rate and duration: phase 1 publication
“The complete response rate and median duration of the complete response across cohorts was 48.6% and 10.4 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the multidose cohorts the complete response rate for the combined groups (every 28 days and weekly × 6) was 63.6% (14 of 22 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response rate: congress report
Complete response at 3 months by schedule: company presentation
| Schedule | Complete response at 3 months |
|---|---|
| Single dose | “3/13 (23%)” |
| Every 28 days | “6/13 (46%)” |
| Weekly × 6 | “7/9 (78%)” |
| Multi-dose (every 28 days and weekly × 6) | “13/22 (59%)” |
| Total | “16/35 (46%)” |
Complete response at 3 months by dose: company presentation
| Dose | Complete response at 3 months |
|---|---|
| 1 × 10^12 viral particles | “8/13 (62%)” |
| 3 × 10^12 viral particles | “4/9 (44%)” |
| 1 × 10^13 viral particles | “4/10 (40%)” |
| 3 × 10^13 viral particles | “0/3 (0%)” |
Duration of complete response: company presentation
Urine GM-CSF and viral genome measurements
“High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events and maximum tolerated dose: phase 1 publication
“Grade 1-2 bladder toxicities were the most common adverse events observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A maximum tolerated dose was not reached.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose-limiting toxicity and flu-like illness: congress report
Adverse events at the first multi-dose level: interim congress report
Study limitations
Summary: limitations of V-0046
- Design: V-0046 was a phase 1, open-label, non-randomized dose-escalation study in 35 participants, with cohorts of three to six participants at each dose and schedule, so efficacy estimates rest on small subgroups (for example, 9 participants on the weekly × 6 schedule).
- Population: eligibility required failure of at least one prior BCG treatment and allowed G2 disease, which differs from the BCG-unresponsive definition used in BOND-003.
- Reported results differ by source: the 2012 publication reports a complete response rate of 48.6% with a median duration of 10.4 months, a 2010 congress report gives 46%, and a 2023 company presentation gives 16 of 35 participants (46%) at 3 months with a median duration of 8.4 months. The multi-dose complete response rate is 63.6% (14 of 22) in the publication and 13 of 22 (59%) in the presentation.
- The association between retinoblastoma phosphorylation and response (81.8%, 9 of 11) comes from an exploratory, retrospective assessment of a subset of 18 participants.
- The registry record lists an estimated primary completion in October 2008 and an estimated enrollment of 75 participants, against 35 participants treated.
- Only the abstract of the 2012 publication is openly available.